SRR23303744
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.460
- ANGIOGENESIS+0.400
- NOTCH_SIGNALING+0.390
- HYPOXIA+0.360
- MYC_TARGETS_V2+0.360
- WNT_BETA_CATENIN_SIGNALING+0.320
- ESTROGEN_RESPONSE_EARLY+0.310
- GLYCOLYSIS+0.310
- APICAL_JUNCTION+0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.280
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.220
- G2M_CHECKPOINT-0.190
- INTERFERON_ALPHA_RESPONSE-0.190
- PROTEIN_SECRETION-0.180
- UV_RESPONSE_DN-0.170
- ANDROGEN_RESPONSE-0.140
- MITOTIC_SPINDLE-0.120
- IL6_JAK_STAT3_SIGNALING-0.090
- E2F_TARGETS-0.070
- PANCREAS_BETA_CELLS-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R111 | — | — | 0.817 |
| 2 | GSM5359427 | — | — | 0.800 |
| 3 | MBCProject_1151_T1_RNA | — | B | 0.779 |
| 4 | MNG412 | — | — | 0.762 |
| 5 | c119f5ef.864c.434b.b515.57c27c7ae949 | — | cohortA1 | 0.741 |
| 6 | MNG754 | — | — | 0.735 |
| 7 | BS_MA2T7ET1 | Spinal Cord Ependymoma | — | 0.724 |
| 8 | 40b92a76-f324-4cdd-8209-517d021acd47 | — | — | 0.721 |
| 9 | BS_196BBNEJ | EPN | Posterior Fossa EPN | 0.719 |
| 10 | R308 | — | — | 0.719 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.460 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.390 | Inavolisib | — uncovered |
| HYPOXIA | 0.360 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.160 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |